Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Welling DB, et al. Among authors: oblinger jl. Laryngoscope Investig Otolaryngol. 2021 Aug 20;6(5):1008-1019. doi: 10.1002/lio2.643. eCollection 2021 Oct. Laryngoscope Investig Otolaryngol. 2021. PMID: 34667843 Free PMC article.
Treatment of vestibular schwannoma cells with ErbB inhibitors.
Bush ML, Burns SS, Oblinger J, Davletova S, Chang LS, Welling DB, Jacob A. Bush ML, et al. Otol Neurotol. 2012 Feb;33(2):244-57. doi: 10.1097/MAO.0b013e31823e287f. Otol Neurotol. 2012. PMID: 22222570 Free PMC article.
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Burns SS, et al. Among authors: oblinger jl. Cancer Res. 2013 Jan 15;73(2):792-803. doi: 10.1158/0008-5472.CAN-12-1888. Epub 2012 Nov 14. Cancer Res. 2013. PMID: 23151902 Free PMC article.
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium. Angus SP, et al. Among authors: oblinger jl. Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046. Neuro Oncol. 2018. PMID: 29982664 Free PMC article.
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Chang LS, et al. Among authors: oblinger jl. Mol Cancer Ther. 2020 Mar;19(3):731-741. doi: 10.1158/1535-7163.MCT-19-0809. Epub 2019 Dec 17. Mol Cancer Ther. 2020. PMID: 31848295 Free PMC article.
49 results